AMA
Smereka S, Jabłoński W, Raszewska J, Osyra P, Wolińska N, Frycz J. Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile. Dermatology Review/Przegląd Dermatologiczny. 2025;112(2):80-82. doi:10.5114/dr.2025.153227.
APA
Smereka, S., Jabłoński, W., Raszewska, J., Osyra, P., Wolińska, N., & Frycz, J. (2025). Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile. Dermatology Review/Przegląd Dermatologiczny, 112(2), 80-82. https://doi.org/10.5114/dr.2025.153227
Chicago
Smereka, Szymon, Wiktor Jabłoński, Julia Raszewska, Paulina Osyra, Natalia Wolińska, and Jan Frycz. 2025. "Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile". Dermatology Review/Przegląd Dermatologiczny 112 (2): 80-82. doi:10.5114/dr.2025.153227.
Harvard
Smereka, S., Jabłoński, W., Raszewska, J., Osyra, P., Wolińska, N., and Frycz, J. (2025). Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile. Dermatology Review/Przegląd Dermatologiczny, 112(2), pp.80-82. https://doi.org/10.5114/dr.2025.153227
MLA
Smereka, Szymon et al. "Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile." Dermatology Review/Przegląd Dermatologiczny, vol. 112, no. 2, 2025, pp. 80-82. doi:10.5114/dr.2025.153227.
Vancouver
Smereka S, Jabłoński W, Raszewska J, Osyra P, Wolińska N, Frycz J. Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile. Dermatology Review/Przegląd Dermatologiczny. 2025;112(2):80-82. doi:10.5114/dr.2025.153227.
